Holen Sie sich die Stockscreener-App
20.15
1.82%
0.36
Schlusskurs vom Vortag:
$19.79
Offen:
$19.73
24-Stunden-Volumen:
370.67K
Relative Volume:
0.67
Marktkapitalisierung:
$564.14M
Einnahmen:
$17.16M
Nettoeinkommen (Verlust:
$-163.62M
KGV:
-3.3141
EPS:
-6.08
Netto-Cashflow:
$-121.61M
1W Leistung:
-2.75%
1M Leistung:
-22.26%
6M Leistung:
+6.78%
1J Leistung:
-44.11%
1-Tages-Spanne:
$19.48
$20.47
1-Wochen-Bereich:
$19.48
$20.47
52-Wochen-Spanne:
$12.21
$40.70
Anaptysbio Inc Stock (ANAB) Company Profile
Firmenname
Anaptysbio Inc
Sektor
Branche
Telefon
858-362-6295
Adresse
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Vergleichen Sie ANAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
20.15 | 560.02M | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.36 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.01 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.31 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.97 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.33 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-07-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-19 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-03-12 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-02-26 | Eingeleitet | BTIG Research | Buy |
| 2024-02-21 | Eingeleitet | Stifel | Buy |
| 2024-02-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-22 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-09-13 | Herabstufung | Truist | Buy → Hold |
| 2022-09-01 | Eingeleitet | Raymond James | Outperform |
| 2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-03-16 | Hochstufung | Truist | Hold → Buy |
| 2021-03-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-03-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-10-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Herabstufung | Jefferies | Buy → Hold |
| 2019-11-08 | Herabstufung | SunTrust | Buy → Hold |
| 2019-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Stifel | Buy → Hold |
| 2018-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-04-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Bestätigt | Stifel | Buy |
| 2018-03-06 | Bestätigt | Stifel | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2018-01-23 | Bestätigt | Credit Suisse | Outperform |
| 2017-11-15 | Eingeleitet | SunTrust | Buy |
| 2017-11-09 | Eingeleitet | Jefferies | Buy |
| 2017-10-11 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Anaptysbio Inc Aktie (ANAB) Neueste Nachrichten
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Trend analysis for AnaptysBio Inc. this weekSwing Trade & Expert Curated Trade Setups - Newser
Fox Run Management L.L.C. Makes New Investment in AnaptysBio, Inc. $ANAB - MarketBeat
Will AnaptysBio Inc. continue its uptrend2025 Buyback Activity & Consistent Profit Focused Trading Strategies - Newser
Can a trend reversal in AnaptysBio Inc. lead to recoveryJuly 2025 WrapUp & AI Powered Buy/Sell Recommendations - Newser
Earnings visualization tools for AnaptysBio Inc.Market Volume Report & Free Weekly Chart Analysis and Trade Guides - Newser
Historical volatility pattern of AnaptysBio Inc. visualizedJuly 2025 WrapUp & Real-Time Volume Trigger Notifications - Newser
How to manage a losing position in AnaptysBio Inc.2025 Top Decliners & Community Consensus Trade Signals - Newser
How to read the order book for AnaptysBio Inc.Weekly Risk Report & Weekly Stock Performance Updates - Newser
Chart based exit strategy for AnaptysBio Inc.Day Trade & Free Weekly Watchlist of Top Performers - Newser
Will AnaptysBio Inc. stock go up soonBreakout Watch & Risk Controlled Swing Trade Alerts - Newser
Will breakout in AnaptysBio Inc. lead to full recoveryJuly 2025 Closing Moves & Free Community Supported Trade Ideas - Newser
What does recent volatility data suggest for AnaptysBio Inc.Quarterly Portfolio Report & Real-Time Volume Analysis - Newser
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Investigational Rosnilimab Emerges as a Novel, Differentiated Treatment Option for Rheumatoid Arthritis - Fierce Biotech
Can machine learning forecast AnaptysBio Inc. recoveryJuly 2025 Highlights & Real-Time Market Sentiment Alerts - Newser
What makes AnaptysBio Inc. stock price move sharplyEarnings Trend Report & Weekly Breakout Opportunity Watchlist - mustnews.co.kr
UBS Group Reiterates Neutral Rating for AnaptysBio (NASDAQ:ANAB) - MarketBeat
Multi asset correlation models including AnaptysBio Inc.Layoff News & Long-Term Growth Stock Strategies - Newser
Is AnaptysBio Inc. a good stock for dollar cost averaging2025 Price Action Summary & Smart Allocation Stock Tips - sundaytimes.kr
Will AnaptysBio Inc. see short term momentumTrade Risk Summary & Consistent Return Strategy Ideas - Newser
How to recover losses in AnaptysBio Inc. stockPortfolio Return Report & Verified High Yield Trade Plans - Newser
Federated Hermes Inc. Lowers Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio Inc. stock trend forecastTrade Volume Summary & Entry Point Strategy Guides - Newser
Wedbush Forecasts AnaptysBio's Q3 Earnings (NASDAQ:ANAB) - MarketBeat
Leerink Partnrs Forecasts Stronger Earnings for AnaptysBio - MarketBeat
Is AnaptysBio Inc. a defensive stock2025 Geopolitical Influence & Daily Profit Maximizing Trade Tips - kangso.co.kr
What technical models suggest about AnaptysBio Inc.’s comebackJuly 2025 Institutional & Momentum Based Trading Ideas - Newser
AnaptysBio’s (ANAB) Neutral Rating Reaffirmed at UBS Group - Defense World
AnaptysBio (NASDAQ:ANAB) Earns Neutral Rating from UBS Group - Defense World
AnaptysBio (NASDAQ:ANAB) Receives Neutral Rating from UBS Group - Defense World
AnaptysBio Inc. Matches Institutional Buying FilterMarket Trend Report & Weekly High Conviction Ideas - 선데이타임즈
UBS Maintains AnaptysBio(ANAB.US) With Hold Rating, Cuts Target Price to $20 - 富途牛牛
UBS Adjusts Price Target on AnaptysBio to $20 From $18, Maintains Neutral Rating - MarketScreener
What is Wedbush's Estimate for AnaptysBio Q4 Earnings? - MarketBeat
AnaptysBio (NASDAQ:ANAB) Shares Down 9.8%Should You Sell? - MarketBeat
UBS Raises AnaptysBio PT to $20, Maintains Neutral Rating - AInvest
Wedbush Raises AnaptysBio (NASDAQ:ANAB) Price Target to $45.00 - MarketBeat
AnaptysBio Receives Hold Rating from Truist Financial with $20 Target - AInvest
Zurcher Kantonalbank Zurich Cantonalbank Sells 660 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
Wedbush Weighs in on AnaptysBio’s Q3 Earnings (NASDAQ:ANAB) - Defense World
Federated Hermes Inc. Has $154,000 Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
What moving averages say about AnaptysBio Inc.Downside Control Plan With Support Analysis - Newser
AnaptysBio Reports Q2 2025 Financial Results and Updates - TipRanks
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $45.00 - Defense World
Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates - 富途牛牛
Finanzdaten der Anaptysbio Inc-Aktie (ANAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Anaptysbio Inc-Aktie (ANAB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| RENTON HOLLINGS | Director |
Aug 08 '25 |
Sale |
19.62 |
10,231 |
200,714 |
4,965 |
2.44%
0.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):